期刊
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
卷 41, 期 1, 页码 206-232出版社
SPRINGER
DOI: 10.1007/s11239-015-1310-7
关键词
DOACs; NOACs; Direct thrombin inhibitors; Factor Xa inhibitors; Antidotes; Care transitions; Bridging anticoagulation; Drug interactions
资金
- Boehringer Ingelheim
- Daiichi Sankyo
- Janssen Pharmaceuticals
The authors of this manuscript first developed a list of pivotal practical questions related to real-world clinical scenarios involving the use of DOACs for VTE treatment. We then performed a PubMed search for topics and key words including, but not limited to, apixaban, antidote, bridging, cancer, care transitions, dabigatran, direct oral anticoagulant, deep vein thrombosis, edoxaban, interactions, measurement, perioperative, pregnancy, pulmonary embolism, reversal, rivaroxaban, switching, \thrombophilia, venous thromboembolism, and warfarin to answer these questions. Non- English publications and publications > 10 years old were excluded. In an effort to provide practical information about the use of DOACs for VTE treatment, answers to each question are provided in the form of guidance statements, with the intent of high utility and applicability for frontline clinicians across a multitude of care settings.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据